THE NON-CONTRACEPTIVE EFFECTS OF THE LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE

被引:29
作者
CHI, IC
FARR, G
机构
[1] Family Health International, Durham, 27709, Research Triangle Park
关键词
D O I
10.1007/BF01984125
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Clinical trials have consistently shown that the IUD that releases 20 mu g levonorgestrel daily (LNG-IUD-20) has a contraceptive efficacy comparable to, if not surpassing, the Copper T380 and the Multiload Copper-375 IUDs. The focus of this review is the device's non-contraceptive effects - the beneficial ones, such as reduction of menorrhagia, a therapeutic effect on dysmenorrhea, and prevention of ectopic pregnancy, as well as the deleterious ones, such as amenorrhea, spotting and irregular bleeding, hormonal side-effects, and functional ovarian cysts. Also discussed are the possibility of a preventive effect on pelvic inflammatory disease, the effects of the IUD on postpartum/lactating women, fertility return after removal and other safety issues. In general, the LNG-IUD-20's non-contraceptive benefits are substantive, carry important medical and public health implications, and far outweigh the device's deleterious effects, which are either medically mild or transient in nature, and can usually be managed satisfactorily by counseling. A better understanding of these effects, both beneficial and deleterious, of this hormone-releasing IUD should lead to more effective patient counseling, which, in turn, should improve user quality of life, minimize unnecessary removals, and maximize continuation of use.
引用
收藏
页码:271 / 285
页数:15
相关论文
共 39 条
[1]  
Chi I-C, An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs, Contraception, 44, pp. 573-88, (1991)
[2]  
Chi I-C, The TCu380A, MLCu375, Nova-T IUDs and the IUD daily releasing 20 μg levonorgestrel —four pillars of future IUD contraception for the nineties and beyond?, Contraception, 47, pp. 325-47, (1993)
[3]  
Anderson K., Odlind V., Rybo G., Levonorgestrel-releasing and copper-releasing (Nova-T) IUDs during five years of use: a randomized comparative study, Contraception, 49, pp. 56-72, (1994)
[4]  
Luukkainen T., Allonen H., Haukamaa M., Et al., Five years' experience with levonorgestrel-releasing IUDs, Contraception, 33, pp. 139-48, (1986)
[5]  
Hatcher R.A., Trussel J., Stewart F., Contraceptive technology update, (1994)
[6]  
Sivin I., Mahgoub S.E., McCarthy T., Et al., Long-term contraception with the levonorgestrel 20 mcg/day (LNG 20) and the Copper T 380Ag intrauterine devices: A five-year randomized study, Contraception, 42, pp. 361-78, (1990)
[7]  
Randomized clinical trials with intrauterine devices (levonorgestrel intrauterine device, LNG), Cu T 380Ag, Cu T 220C, Cu T 200B. A 36-month study, Contraception, 39, pp. 37-52, (1989)
[8]  
Nilsson C.G., Allonen H., Diaz J., Luukkainen T., Two-years experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device. A randomized comparative performance study, Fertil Steril., 39, pp. 187-92, (1983)
[9]  
Luukkainen T., Allonen H., Haukamaa M., Et al., Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study, Contraception, 36, pp. 169-79, (1987)
[10]  
Toivonen J., Luukkainen T., Allonen H., Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices, Obstet Gynecol., 77, pp. 261-4, (1991)